

## Anti-VISTA [13F3] VivopureX 100 mg Ab01420-3.3-VXB

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Mouse IgG2b, [Fc Silent™](#), Lambda

**Clone Number:** 13F3

**Alternative Name(s) of Target:** PD-1H; V-domain Ig suppressor of T cell activation; V-type immunoglobulin domain-containing suppressor of T-cell activation; Platelet receptor Gi24; V-set domain-containing immunoregulatory receptor; V-set immunoregulatory receptor; Vsir; Dies1

**UniProt Accession Number of Target Protein:** Q9D659

**Published Application(s):** Blocking, ELISA, FC

**Published Species Reactivity:** Mouse

**Immunogen:** This antibody was raised by immunising Armenian hamsters with EL4 cells overexpressing VISTA-RFP, and VISTA-Ig fusion protein.

**Specificity:** This antibody is specific for murine VISTA.

**Application Notes:** The specificity of this antibody has been confirmed in both ELISA and flow cytometry (Wang et al, 2011). This antibody has been used in flow cytometric analysis to assess VISTA expression in murine lupus models (Ceeraz et al, 2017; Sergent et al, 2018) and mice infected with HSV-1 (Srivastava et al, 2018). This antibody has been shown to block VISTA, and enhances T cell proliferation in vitro (Wang et al, 2011). In mice models, this antibody exacerbates experimental autoimmune encephalomyelitis (Wang et al, 2011) and murine arthritis and lupus disease progression (Sergent et al, 2018). The use of this antibody to achieve a VISTA blockade enhances anti-tumour immune responses in mice models of both transplantable and inducible melanoma, suppressing tumour growth (LeMercier et al, 2014).

**Antibody First Published in:** Wang et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011 Mar 14;208(3):577-92. [PMID:21383057](#)

**Note on publication:** Describes the original generation of this antibody, and its exacerbation of EAE disease progression.

## Product Form

**Size:** 100 mg VivopureX products are produced at high purity (>98%), low endotoxin (<0.5 EU/mg) and are formulated without preservatives. These antibodies are chimerized to have an Fc domain matching their target species to reduce immunogenicity and give you the optimal effector function for your experiment. As a result VivopureX products are the ideal choice for in vivo research applications.

**Purification:** Protein A affinity purified

**Supplied In:** PBS only.

**Storage Recommendation:** All VivopureX products are formulated in PBS only without addition of preservatives. To ensure optimal storage and prevent microbial contamination, only open and dispense under sterile conditions. Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** ≥1mg (see vial label for exact conc)

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.